India-NZ FTA Wins Medtech Support Despite CDSCO Recognition Gap

India’s medical technology industry has welcomed the India–New Zealand Free Trade Agreement (FTA), calling it a positive step toward boosting trade and expanding export opportunities. However, industry leaders say a key regulatory gap remains — the agreement does not recognise India’s drug regulator, the Central Drugs Standard Control Organisation (CDSCO).

The FTA is expected to strengthen trade relations between India and New Zealand while creating new opportunities for Indian medical device companies. One of the agreement’s major highlights is New Zealand’s acceptance of inspection reports from several global regulators, including the US Food and Drug Administration (FDA), European authorities, the United Kingdom, and Canada.

For medical device manufacturers, this recognition can make exports easier by reducing repeated inspections and speeding up approval processes. Industry experts believe this could help companies save time, lower regulatory compliance costs, and improve access to global healthcare markets.

Also Read: Max Healthcare Joins Global COMBAT Dengue Research Initiative

Despite these benefits, the absence of CDSCO recognition has become a point of concern for India’s medtech sector. Stakeholders believe that including India’s regulator would have strengthened trust in Indian manufacturing standards and given local companies smoother entry into the New Zealand market.

Industry representatives say recognition of CDSCO inspections could have reduced regulatory duplication and improved the global acceptance of Indian medical products. Without it, Indian manufacturers may still need to undergo additional checks, which could delay approvals and increase operational costs.

The Indian medtech industry has been growing rapidly in recent years, supported by domestic manufacturing initiatives and rising global demand. Companies now see international trade agreements as an important way to expand their presence in foreign markets.

Experts believe the FTA is still a significant development for the healthcare and medical device sectors, especially as it introduces a dedicated chapter on healthcare innovation and traditional medicine services. This section may encourage collaboration in medical services and cross-border partnerships between the two countries.

While the agreement marks progress in bilateral trade relations, industry leaders feel future discussions should focus on greater regulatory alignment. Including CDSCO in mutual recognition frameworks could strengthen India’s position in global healthcare trade and provide a more level playing field for domestic manufacturers.